Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity.

Karnell JL, Albulescu M, Drabic S, Wang L, Moate R, Baca M, Oganesyan V, Gunsior M, Thisted T, Yan L, Li J, Xiong X, Eck SC, de Los Reyes M, Yusuf I, Streicher K, Müller-Ladner U, Howe D, Ettinger R, Herbst R, Drappa J.

Sci Transl Med. 2019 Apr 24;11(489). pii: eaar6584. doi: 10.1126/scitranslmed.aar6584.

PMID:
31019027
2.

Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.

Burmester GR, McInnes IB, Kremer JM, Miranda P, Vencovský J, Godwood A, Albulescu M, Michaels MA, Guo X, Close D, Weinblatt M.

Arthritis Rheumatol. 2018 May;70(5):679-689. doi: 10.1002/art.40420. Epub 2018 Mar 31.

3.

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.

Weinblatt ME, McInnes IB, Kremer JM, Miranda P, Vencovsky J, Guo X, White WI, Ryan PC, Godwood A, Albulescu M, Close D, Burmester GR.

Arthritis Rheumatol. 2018 Jan;70(1):49-59. doi: 10.1002/art.40323.

4.

[Ergometric and hemodynamic tests and resumption of activities in myocardial infarct patients under 55 years of age].

Dimitriu CG, Nicolau V, Chirilă P, Karassi A, Zeană C, Albulescu M.

Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna. 1981 Sep-Oct;33(5):345-8. Romanian. No abstract available.

PMID:
6122245

Supplemental Content

Loading ...
Support Center